Core Viewpoint - The company Baiotai (688177.SH) has signed a licensing and commercialization agreement with STADA for its BAT1806 (Tocilizumab) injection, granting STADA exclusive commercialization rights in several regions, including the EU, Switzerland, the UK, parts of Europe, the MENA region, and some CIS countries [1][2] Group 1: Agreement Details - The total amount of upfront and milestone payments can reach up to €136 million, which includes an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million, along with a double-digit percentage of net sales as revenue sharing [1] - BAT1806 (Tocilizumab) is a biosimilar developed according to guidelines from the NMPA in China, FDA in the US, and EMA in Europe, targeting the IL-6 receptor [1] Group 2: STADA Overview - STADA is a well-established European pharmaceutical company headquartered in Germany, focusing on three strategic pillars: consumer health, generics, and specialty pharmaceuticals [2] - In the fiscal year 2024, STADA achieved a group sales revenue of €4.059 billion, with an adjusted EBITDA of €886 million, and employs approximately 11,649 people globally [2] - The collaboration aims to rapidly convert the company's research achievements into economic benefits through commercial partnerships and licensing, enhancing the company's core competitiveness [2]

Core Viewpoint - The company Baiotai (688177.SH) has signed a licensing and commercialization agreement with STADA Arzneimittel AG for its BAT1806 (Tocilizumab) injection, granting STADA exclusive commercialization rights in several regions, which is expected to positively impact the company's future performance and enhance its global commercialization and profitability [1] Group 1 - The agreement involves the exclusive commercialization rights of BAT1806 (Tocilizumab) injection in the EU, Switzerland, the UK, parts of Europe, the MENA region, and certain CIS countries [1] - The total transaction amount can reach up to €136 million, including an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million, along with a double-digit percentage of net sales as revenue sharing [1] - The agreement will take effect after approval by the company's shareholders [1]

智通财经APP讯，百奥泰(688177.SH)发布公告，公司与STADA Arzneimittel AG(简称"STADA")签署授 权许可与商业化协议，将公司的BAT1806(托珠单抗)注射液在欧盟、瑞士、英国、其它部分欧洲国家、 部分中东与北非地区(MENA)和部分独立国家联合体(CIS)国家市场的独占的产品商业化权益有偿许可给 STADA。协议的签订预计将对公司未来业绩产生积极影响，有利于提升公司全球商业化及盈利能力。 交易标的名称：BAT1806(托珠单抗)注射液在欧盟、瑞士、英国、其它部分欧洲国家、部分中东与北非 地区(MENA)和部分独立国家联合体(CIS)国家市场的独占的产品商业化权益。交易金额：首付款及里程 碑款总金额最高至1.36亿欧元，其中包括850万欧元首付款、累计不超过1.275亿欧元里程碑付款，以及 净销售额的两位数百分比作为收入分成。协议生效条件：经公司股东会审议通过后生效。 ...